GlaxoSmithKline | Boss faces ousting by 'activist investors' - here's why leaders should be worried

One of GlaxoSmithKline's smaller investors is currently looking to oust its CEO.

Whilst they may not seem to be a threat, Exxon was recently overruled by a similar group. They part of a new wave of 'activist investors', looking to shape the future of business. Will they be successful? Read on to find out...